- Home
- OVID
as 12-18-2024 12:41pm EST
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 73.1M | IPO Year: | 2017 |
| Target Price: | $4.04 | AVG Volume (30 days): | 210.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.68 - $4.10 | Next Earning Date: | 11-12-2024 |
| Revenue: | $631,695 | Revenue Growth: | 113.21% |
| Revenue Growth (this year): | 71.38% | Revenue Growth (next year): | 5144.81% |
Latest Ovid Therapeutics Inc. News
OVID Breaking Stock News: Dive into OVID Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
3 US Penny Stocks With Market Caps Over $20M
GlobeNewswire
16 days ago
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
Zacks
a month ago
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
Simply Wall St.
a month ago
US Penny Stocks To Watch This November 2024
GlobeNewswire
2 months ago
Ovid Therapeutics to Host Investor Event
Simply Wall St.
3 months ago
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?
GlobeNewswire
3 months ago
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
Compare OVID vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OVID Ovid Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.